Edgar Haug is a founding partner of Frommer Lawrence & Haug LLP and its Managing Partner since 2003.
Mr. Haug has been engaged in litigation and counseling involving diverse aspects of intellectual property and competition law for many of the world’s leading companies. He litigates in complex technical fields, including pharmaceuticals and biotechnology, semi-conductors and associated manufacturing equipment, shape memory alloys, e-commerce, automotive designs and consumer electronics. He also counsels clients regularly in due diligence investigations.
Mr. Haug is nationally recognized as a trial lawyer and consultant specializing in pharmaceutical patent litigation under the Hatch-Waxman Amendments to the Federal Food, Drug & Cosmetic Act. He has represented clients involved in patent enforcement as well as regulatory and patent challenges involving many of the world's largest selling pharmaceuticals including Zantac, Paxil, Prozac, Omeprazole, Megace, Adderall XR, Neurontin, EPO, Trovax, Oxytrol, Carbatrol, and Duoneb.
Mr. Haug has substantial experience in both bench and jury trials as well as appellate practice. He has also been involved in proceedings before foreign jurisdictions including, the UK High Court, the German Federal Supreme Court, and the Tokyo High Court.
Mr. Haug has been a regular faculty member of the Practising Law Institute teaching all aspects of trial advocacy in patent cases. He is also a frequent lecturer for many professional organizations and has been a keynote speaker for the Bear Stearns HealthCare conferences in New York, London, Paris, and Zurich. He recently was appointed to the Board of Directors of the Federal Circuit Bar Association.
Edgar Haug has been listed in the New York Super Lawyers 2008 through 2010 Metro Editions.
